TEVA Teva Pharmaceutical Industries Ltd
Price (delayed)
$18.08
Market cap
$20.48B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.42
Enterprise value
$37.15B
Highlights
TEVA's net income has surged by 80% year-on-year and by 5% since the previous quarter
Teva Pharmaceutical Industries's EPS has surged by 80% YoY and by 7% QoQ
Teva Pharmaceutical Industries's equity has decreased by 13% QoQ and by 10% YoY
TEVA's quick ratio is down by 12% YoY and by 2.1% from the previous quarter
Key stats
What are the main financial stats of TEVA
Market
Valuations
Earnings
Shares outstanding
1.13B
Market cap
$20.48B
Enterprise value
$37.15B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.22
Price to sales (P/S)
1.26
EV/EBIT
32.27
EV/EBITDA
16.65
EV/Sales
2.28
Revenue
$16.29B
EBIT
$1.15B
EBITDA
$2.23B
Free cash flow
$679M
Per share
Balance sheet
Liquidity
EPS
-$0.42
Free cash flow per share
$0.6
Book value per share
$5.61
Revenue per share
$14.38
TBVPS
$17.65
Total assets
$41.34B
Total liabilities
$34.77B
Debt
$18.92B
Equity
$6.36B
Working capital
-$1.41B
Debt to equity
2.98
Current ratio
0.89
Quick ratio
0.46
Net debt/EBITDA
7.47
Margins
Efficiency
Dividend
EBITDA margin
13.7%
Gross margin
49.5%
Net margin
-2.9%
Operating margin
5.2%
Return on assets
-1.1%
Return on equity
-6.8%
Return on invested capital
4.6%
Return on capital employed
4.1%
Return on sales
7.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TEVA stock price
How has the Teva Pharmaceutical Industries stock price performed over time
Intraday
-1.9%
1 week
-4.19%
1 month
6.92%
1 year
90.72%
YTD
73.18%
QTD
11.26%
Financial performance
How have Teva Pharmaceutical Industries's revenue and profit performed over time
Revenue
$16.29B
Gross profit
$8.06B
Operating income
$855M
Net income
-$476M
Gross margin
49.5%
Net margin
-2.9%
TEVA's operating income has soared by 171% YoY
The operating margin has soared by 165% YoY
The net margin has surged by 81% year-on-year and by 6% since the previous quarter
TEVA's net income has surged by 80% year-on-year and by 5% since the previous quarter
Growth
What is Teva Pharmaceutical Industries's growth rate over time
Valuation
What is Teva Pharmaceutical Industries stock price valuation
P/E
N/A
P/B
3.22
P/S
1.26
EV/EBIT
32.27
EV/EBITDA
16.65
EV/Sales
2.28
Teva Pharmaceutical Industries's EPS has surged by 80% YoY and by 7% QoQ
TEVA's price to book (P/B) is 168% higher than its 5-year quarterly average of 1.2 and 53% higher than its last 4 quarters average of 2.1
Teva Pharmaceutical Industries's equity has decreased by 13% QoQ and by 10% YoY
The P/S is 80% above the 5-year quarterly average of 0.7 and 40% above the last 4 quarters average of 0.9
TEVA's revenue is up by 8% year-on-year
Efficiency
How efficient is Teva Pharmaceutical Industries business performance
Teva Pharmaceutical Industries's return on sales has surged by 196% YoY and by 122% QoQ
The company's return on invested capital has surged by 130% QoQ
Teva Pharmaceutical Industries's return on assets has surged by 80% YoY and by 8% QoQ
TEVA's ROE has soared by 77% YoY and by 2.9% from the previous quarter
Dividends
What is TEVA's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history
Special dividends are included in TTM DPS and yield
Financial health
How did Teva Pharmaceutical Industries financials performed over time
The total assets is 19% greater than the total liabilities
Teva Pharmaceutical Industries's current ratio has decreased by 13% YoY
TEVA's quick ratio is down by 12% YoY and by 2.1% from the previous quarter
The debt is 198% greater than the equity
Teva Pharmaceutical Industries's equity has decreased by 13% QoQ and by 10% YoY
The debt has declined by 10% year-on-year and by 5% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.